Cargando…

Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection

BACKGROUND: It has been known that there are microecology disorders during lung cancer development. Theoretically, intratumoral microbiota (ITM) can impact the lung cancer (LC) survival and treatment efficacy. This study conducted a follow-up investigation of non-small cell lung cancer (NSCLC) patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Miao, Zhang, Yan, Sun, Yi, Wang, Shaochun, Liang, Huan, Han, Yaguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844104/ https://www.ncbi.nlm.nih.gov/pubmed/35178229 http://dx.doi.org/10.1155/2022/5466853

Ejemplares similares

Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
por: Zhang, Miao, et al.
Publicado: (2022)

Surgical and survival outcomes of lung cancer patients with intratumoral lung abscesses
por: Yamanashi, Keiji, et al.
Publicado: (2017)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes
por: Isaeva, O. I., et al.
Publicado: (2019)

Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy
por: Yang, Li, et al.
Publicado: (2023)

Intratumor heterogeneity is associated with less CD8(+) T cell infiltration and worse survival in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2022)

Intratumoral Heterogeneity in Lung Cancer
por: Lv, Xiaodi, et al.
Publicado: (2023)

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
por: Park, Sehhoon, et al.
Publicado: (2018)

Intratumoral Microbiota-Host Interactions Shape the Variability of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma in Recurrence and Metastasis
por: Zhou, Xiangfeng, et al.
Publicado: (2023)

The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2020)

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival
por: Shen, Xia-Bo, et al.
Publicado: (2019)

Intratumor Heterogeneity in Early Lung Adenocarcinoma
por: Senosain, Maria-Fernanda, et al.
Publicado: (2020)

Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer
por: Lim, Jing Shan, et al.
Publicado: (2017)

Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma
por: Gopal, Priyanka, et al.
Publicado: (2022)

DNA methylation intratumor heterogeneity in localized lung adenocarcinomas
por: Quek, Kelly, et al.
Publicado: (2017)

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
por: Zhou, Fei, et al.
Publicado: (2018)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer
por: Szentkereszty, Márton, et al.
Publicado: (2019)

Synchronous Microwave Ablation Combined With Cisplatin Intratumoral Chemotherapy for Large Non-Small Cell Lung Cancer
por: Huang, Guanghui, et al.
Publicado: (2022)

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
por: Liu, Yang, et al.
Publicado: (2023)

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
por: Aboshi, Masayuki, et al.
Publicado: (2014)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer
por: Wang, Fang, et al.
Publicado: (2012)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
por: Verduyn, S Cora, et al.
Publicado: (2012)

Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy
por: Singh, Apurva, et al.
Publicado: (2022)

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
por: Ehrlich, Debra, et al.
Publicado: (2014)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2020)

Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions
por: Kuan, Feng-Che, et al.
Publicado: (2016)

Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2021)

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
por: He, Yayi, et al.
Publicado: (2020)

Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
por: Jia, Qingzhu, et al.
Publicado: (2018)

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer
por: Rakaee, Mehrdad, et al.
Publicado: (2016)

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer
por: Gregorc, Vanesa, et al.
Publicado: (2021)

Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity
por: Kanaki, Zoi, et al.
Publicado: (2021)

Analysis of intratumor heterogeneity unravels lung cancer evolution
por: de Bruin, Elza C, et al.
Publicado: (2015)

Visualizing intratumoral injections in lung tumors by endobronchial ultrasound
por: Mori, Vitor, et al.
Publicado: (2023)

Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma
por: Hua, Xing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d5pqdrd0p6kgf6t36mqm2ikgni